Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922542 · ClinicalTrials.gov registry record · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
A Phase 2 study of Keratoconus and Ectasia Corneal, sponsored by Price Vision Group.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 510
- Enrollment target
- 1
- Study location
NCT03922542 is a Phase 2 study of Keratoconus and Ectasia Corneal that is actively recruiting participants, run by Price Vision Group. The registered enrollment target is 510 participants, below the 1,156-participant average among 21 other Keratoconus trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03922542, a Phase 2 study of Keratoconus and Ectasia Corneal, is actively recruiting participants, sponsored by Price Vision Group.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 510 participants
- Enrollment target
- 1
- Study location
Study Summary
The study objective is to compare accelerated and standard corneal crosslinking for treatment of progressive keratoconus or corneal ectasia.
Conditions Studied
Interventions
- COMBINATION_PRODUCT riboflavin 0.1%
- COMBINATION_PRODUCT Riboflavin 0.1%
Study Locations (1)
Indiana
- Price Vision Group - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2019-04-16 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03922542
The ClinicalTrials.gov registry entry for NCT03922542 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,156-participant average among 21 other Keratoconus trials with a reported enrollment target (56% lower). The listed sponsor is Price Vision Group, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Keratoconus appearing as the primary indexed condition, and to 2 interventions - of which riboflavin 0.1% is the first listed.
NCT03922542 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT03922542 about?
NCT03922542 is a clinical study titled "Comparison of Standard vs. Accelerated Corneal Crosslinking". The study objective is to compare accelerated and standard corneal crosslinking for treatment of progressive keratoconus or corneal ectasia.
What is the current status of trial NCT03922542?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 510 participants. The study started on 2019-04-16. Estimated completion is 2026-07-01.
What conditions does trial NCT03922542 study?
This clinical trial studies the following conditions: Keratoconus, Ectasia Corneal.
What interventions are being tested in trial NCT03922542?
The interventions under investigation include: riboflavin 0.1% (COMBINATION_PRODUCT), Riboflavin 0.1% (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03922542?
This trial is sponsored by Price Vision Group, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03922542 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning
RECRUITING · Phase 2
-
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
RECRUITING · Phase 2
-
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia
RECRUITING · Phase 2
-
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
RECRUITING
-
OCT in Diagnosis of Irregular Corneas
RECRUITING
-
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.